Kisspeptin 10mg Review

Kisspeptin-10 (KP-10) occupies a singular position in reproductive neuroendocrinology research. As the smallest biologically active fragment of the KISS1 peptide family, this ten-amino-acid decapeptide binds with nanomolar affinity to the GPR54 receptor (also called KISS1R) and reliably drives gonadotropin-releasing hormone (GnRH) secretion in every vertebrate model tested to date. ^[1] Laboratory groups studying hypogonadotropic hypogonadism, puberty timing, or the relationship between metabolic status and reproductive function have used KP-10 as a chemical probe for more than two decades, and the compound continues to appear in emerging work on sexual behavior, mood, and bone metabolism. ^[2]

This review evaluates the 10 mg vial offered by Apollo Peptide Sciences under the kisspeptin-10mg listing. It covers the peptide's structural chemistry, receptor pharmacology, key preclinical and clinical research data, pharmacokinetic characteristics, quality-verification expectations, and research reconstitution guidance. Every section is framed for laboratory use only.

Editor's Verdict

Kisspeptin-10 is among the most mechanistically well-characterized neuropeptides available as a research reagent. Its role as the proximate upstream activator of GnRH neurons makes it irreplaceable for any laboratory investigating HPG-axis regulation. The 10 mg vial from Apollo Peptide Sciences is sized appropriately for rodent in-vivo dosing studies and for multiple in-vitro binding or signaling assays, and the $40.00 price point is competitive for a lyophilized, HPLC-verified decapeptide at this quantity.

The principal limitations researchers should factor into study design are KP-10's very short plasma half-life (typically below five minutes in rodent blood), its modest blood-brain barrier penetration relative to longer kisspeptin fragments such as KP-54, and documented cross-reactivity at neuropeptide FF (NPFF) receptors that can complicate pharmacological interpretation. ^[3] None of these limitations diminish the peptide's research utility when experimental design accounts for them.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Discovery and nomenclature

Kisspeptin was first characterized in 1996 as the protein product of the KISS1 gene, which was originally identified as a metastasis-suppressor gene in melanoma and breast cancer cell lines. The name "kisspeptin" was coined by Gottsch and Bhatt to reflect both the Hershey, Pennsylvania origin of the KISS1 gene discovery and the peptide's C-terminal RF-amide motif. ^[4] The 145-amino-acid precursor protein undergoes post-translational cleavage by proprotein convertases to yield at least four biologically active fragments: KP-54 (the longest and most abundant in circulation), KP-14, KP-13, and KP-10 (the shortest). All four fragments share an identical C-terminal decapeptide sequence and therefore share identical receptor pharmacology; the differences among them are largely pharmacokinetic rather than mechanistic. ^[5]

Sequence, conformation, and the C-terminal RF-amide

The KP-10 sequence is Tyr1-Asn2-Trp3-Asn4-Ser5-Phe6-Gly7-Leu8-Arg9-Phe10-NH2. The C-terminal amidation is essential for biological activity; the free-acid form displays dramatically reduced potency at GPR54. ^[1] The RF-amide motif (Arg9-Phe10-NH2) is structurally homologous to the RF-amide family of neuropeptides, which explains KP-10's documented cross-reactivity at neuropeptide FF receptors NPFF1R and NPFF2R, a fact that must be considered when designing receptor-selectivity experiments. ^[3]

Nuclear magnetic resonance studies in aqueous solution indicate that KP-10 adopts a largely unstructured conformation in free solution but forms a turn-like structure near the C-terminus that is thought to be the receptor-binding pharmacophore. Truncation studies have confirmed that the minimal sequence retaining meaningful GPR54 activity is the C-terminal pentapeptide (Phe6-Gly7-Leu8-Arg9-Phe10-NH2), though full-length KP-10 retains substantially higher potency. ^[4] The Trp3 residue contributes to receptor binding but is not strictly indispensable; substitution at this position modulates potency without abolishing activity. Researchers developing structure-activity-relationship (SAR) probes should note these constraints when commissioning custom analogs.

Molecular weight and physicochemical properties

KP-10 has a molecular formula of C63H83N17O13 and a molecular weight of approximately 1302.44 Da (free base). It carries a net positive charge at physiological pH due to the Arg9 residue (pKa ~12.5) and the free N-terminal amine, giving it moderate aqueous solubility (readily dissolved in water or physiological saline at concentrations used in research, typically 0.1-1.0 mg/mL). The peptide is susceptible to proteolytic degradation by endopeptidases, including neprilysin (neutral endopeptidase 24.11) and dipeptidyl peptidase IV analogs, which largely account for its short plasma half-life. ^[6] Lyophilized KP-10 is stable at -20°C for at least two years when stored desiccated and protected from light; the Trp3 residue is the primary oxidation-sensitive site and warrants protection from prolonged UV exposure.

Mechanism of Action

GPR54 / KISS1R receptor binding

Kisspeptin-10 is an endogenous agonist at GPR54, a class A G-protein-coupled receptor (GPCR) encoded by the KISS1R gene on chromosome 19p13.3 in humans. ^[5] The receptor was identified as an orphan GPCR in 1999 and deorphanized in 2001 when two independent groups demonstrated that kisspeptins were its cognate ligands. Loss-of-function mutations in KISS1R cause autosomal recessive hypogonadotropic hypogonadism and pubertal failure in humans and mice, which established KISS1R signaling as a non-redundant prerequisite for the onset of puberty and maintenance of reproductive function. ^[2]

KP-10 binds GPR54 with an EC50 in the low nanomolar range (approximately 1-4 nM in cell-based Gq/11 assays, varying somewhat by assay system and cell type). ^[4] Binding is competitive and reversible, consistent with classical agonist pharmacology. KP-10 achieves maximal receptor activation (Emax comparable to KP-54) at equimolar concentrations, confirming it as a full agonist rather than a partial agonist. The shorter plasma stability of KP-10 relative to KP-54 means that in-vivo exposure after equivalent administered doses is lower for KP-10, which has sometimes been misinterpreted as lower intrinsic efficacy.

Downstream signaling cascade

GPR54 couples primarily to Gq/11 proteins. Upon KP-10 binding, the activated Gq subunit stimulates phospholipase C-beta (PLCβ), generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). ^[7] This classical Gq/11-PLC-IP3 cascade is the primary transduction pathway in GnRH neurons, where it depolarizes the cell membrane through TRP channel activation and drives action potential firing, ultimately releasing GnRH into the hypophyseal portal circulation.

Secondary signaling pathways include mitogen-activated protein kinase (MAPK/ERK) activation, observed in GPR54-transfected heterologous cell systems and in certain peripheral tissues. ^[8] Prolonged or high-frequency kisspeptin stimulation can also trigger beta-arrestin-mediated receptor internalization, which provides a molecular basis for the receptor desensitization observed with continuous (non-pulsatile) kisspeptin infusion in in-vivo studies. This receptor internalization/desensitization phenomenon has significant implications for study design: pulsatile or acute bolus delivery paradigms sustain LH responses far more effectively than continuous infusion. ^[9]

GnRH neuron activation and HPG-axis cascade

GnRH neurons in the hypothalamus express GPR54 at high levels, and KP-10 acts on these neurons both directly and indirectly through kisspeptin interneurons in the arcuate nucleus (KNDy neurons co-expressing kisspeptin, neurokinin B, and dynorphin). ^[10] KNDy neurons are now recognized as the intrinsic pulse generator for GnRH secretion; kisspeptin released from KNDy axon terminals drives episodic GnRH pulses that, in turn, drive pituitary LH pulses.

Exogenous KP-10 introduced into this system causes a dose-dependent, rapid-onset increase in plasma LH, reflecting GnRH release into portal blood followed by LH secretion from gonadotropes. In male rodents, a single IV bolus of KP-10 elevates LH within 5-10 minutes, with peak LH occurring at approximately 15-30 minutes and return to baseline within 60-90 minutes. ^[11] In female rodents, the magnitude of the LH response varies across the estrous cycle, being largest at proestrus, when endogenous estradiol exerts its positive feedback on kisspeptin/GPR54 signaling. The GnRH-dependence of this response is confirmed by its complete blockade with GnRH antagonists (e.g., cetrorelix, antide), and the pituitary-dependence is confirmed by hypophysectomy abolishing the LH rise despite intact hypothalamic GnRH secretion. ^[12]

Tissue distribution of GPR54

While GPR54 expression is highest in the hypothalamus, the receptor is expressed in multiple peripheral tissues, and KP-10 exerts effects beyond the HPG axis that are relevant to researchers studying non-reproductive endpoints. ^[5] Documented expression sites include:

• Anterior pituitary gonadotropes (direct LH/FSH secretion independent of GnRH)
• Pancreatic islet beta cells (modulation of insulin secretion)
• Placenta (very high expression; kisspeptin is a major placental product during pregnancy)
• Liver and adipose tissue (metabolic signaling)
• Heart and vasculature (cardiovascular effects documented in animal models)
• Bone (osteoblast and osteoclast modulation)
• Olfactory bulb and limbic structures (behavior modulation)

The cardiovascular expression is particularly relevant to safety research. KP-10 has been reported to cause dose-dependent negative inotropic effects and changes in coronary vascular tone in isolated rodent heart preparations, an effect attributed at least in part to NPFF receptor cross-reactivity. ^[13] Researchers using high-dose or repeated KP-10 administration in rodent in-vivo studies should include cardiovascular monitoring endpoints.

What the Research Says

Study 1: Gottsch et al. (2004), Rodent in-vivo LH stimulation

Gottsch and colleagues published one of the foundational characterizations of KP-10's in-vivo neuroendocrine activity in mice. ^[11] The study used adult male and female C57BL/6 mice and administered KP-10 via intracerebroventricular (ICV) injection at doses ranging from 0.1 to 10 nanomoles per animal. The key endpoint was plasma LH measured by radioimmunoassay at 15, 30, and 60 minutes post-injection.

Results showed a dose-dependent increase in plasma LH, with the 10 nmol ICV dose producing LH elevations approximately 10-fold above vehicle control in males and up to 20-fold in proestrous females. The response was completely abolished by pre-treatment with the GnRH antagonist acyline, confirming that the LH rise was entirely GnRH-dependent. Ovariectomized mice with estradiol replacement showed larger responses than oil-treated controls, providing early in-vivo evidence for the positive-feedback interaction between estrogen and the kisspeptin/GPR54 system.

A critical limitation of this study was its exclusive reliance on ICV administration, which bypasses the blood-brain barrier and achieves hypothalamic concentrations not replicable by systemic injection. The peripheral-versus-central route difference is now well established, and subsequent work by Irwig et al. confirmed that intravenous KP-10 doses must be substantially higher (by one to two orders of magnitude) than ICV doses to achieve comparable LH responses, largely because of rapid plasma clearance before central delivery. This distinction is fundamental to interpreting dose comparisons across studies.

Study 2: Dhillo et al. (2005), Human volunteer clinical data

Dhillo and colleagues conducted one of the first intravenous KP-10 studies in humans, administering single bolus doses of 0.1, 0.3, and 1.0 nmol/kg to healthy male and female volunteers. ^[14] This was a randomized, dose-escalation design with cross-over elements, n=6 per dose cohort, with primary endpoints of plasma LH, FSH, and testosterone (in males) measured over four hours post-injection.

All three doses produced statistically significant increases in plasma LH in both sexes. The 1.0 nmol/kg dose produced the largest responses: mean LH increased approximately 4-fold above baseline in males (peak at 30-45 minutes) and approximately 6-fold in females in the follicular phase. FSH showed a smaller but statistically significant rise. Testosterone rose significantly in males at the highest dose, with a two-hour delay consistent with the known lag between LH secretion and testicular steroidogenesis. No serious adverse events were reported at any dose; mild transient facial flushing was noted in two subjects at 1.0 nmol/kg.

This study was foundational in demonstrating that the rodent pharmacology of KP-10 translates to primates, validating the preclinical models. Its limitations include small sample sizes (n=6 per group) and lack of longer-term follow-up. Researchers should also note that this clinical study was conducted under full regulatory and ethics approval and represents investigational human data; it does not constitute evidence that KP-10 is safe or appropriate for non-clinical self-administration.

Study 3: Pielecka-Fortuna et al. (2008), Electrophysiology of GnRH neurons

Pielecka-Fortuna and colleagues used whole-cell patch-clamp electrophysiology in GnRH-GFP transgenic mice to characterize the direct membrane effects of KP-10 on identified GnRH neurons. ^[10] This in-vitro slice preparation allowed direct measurement of membrane potential, action potential frequency, and ion channel currents in response to KP-10 applied at concentrations of 10 nM, 100 nM, and 1 µM.

At 100 nM, KP-10 depolarized GnRH neurons by a mean of 8-12 mV and increased action potential firing frequency approximately 3-fold compared to vehicle-treated controls. The depolarization was sustained for 5-15 minutes before returning toward resting potential. Ion substitution experiments and pharmacological blockers identified a major contribution from TRP (transient receptor potential) channels, consistent with the known Gq/11-IP3-calcium signaling mechanism. A subset of GnRH neurons (approximately 30%) showed no response to KP-10, suggesting functional heterogeneity within the GnRH neuron population.

These electrophysiological data provided the cellular mechanism underlying the LH-stimulatory effects observed in in-vivo studies and established that at least a portion of kisspeptin's action is direct (not exclusively through interneurons). The primary limitation of this preparation is that brain slice conditions may not fully recapitulate in-vivo network dynamics, particularly the influence of KNDy interneurons on GnRH neuron activity. Subsequent in-vivo fiber photometry studies have extended and refined these findings in awake, freely moving animals.

Study 4: Caraty et al. (2007), Pulsatile KP-10 infusion in ovariectomized ewes

Caraty and colleagues administered pulsatile IV infusions of KP-10 to ovariectomized ewes during anestrus, a model that allows isolation of the kisspeptin-GnRH-LH axis from confounding gonadal steroid feedback. ^[12] Ewes received KP-10 infusions (250 µg per pulse, once every 2 hours) for up to 24 hours, with serial blood sampling via jugular catheter for LH measurement by RIA.

Each KP-10 pulse produced a discrete LH pulse within 5-10 minutes, with LH peak concentrations 5-8 fold above baseline. Remarkably, pulsatile delivery maintained LH pulsatility over the full 24-hour observation window without evidence of desensitization, in sharp contrast to continuous infusion protocols that produced tachyphylaxis within 3-4 hours. This key finding established the importance of pulsatile delivery for maintaining kisspeptin's neuroendocrine efficacy and directly paralleled the known requirement for pulsatile GnRH in sustaining pituitary gonadotropin secretion.

FSH was also elevated, but the response was less pulsatile and showed a slower rise over 8-12 hours, consistent with FSH's longer plasma half-life and the lower sensitivity of FSH synthesis to acute GnRH pulses. This study had an observational window of 24 hours and did not examine longer-term effects on gonadal function. Later sheep studies by the same group demonstrated that sustained pulsatile KP-10 administration over days to weeks could reinstate estrous cyclicity in chronically anovulatory ewes, extending the functional significance of the acute pulsatility findings.

Study 5: Curtis et al. (2010), Metabolic modulation of KP-10 responses

Curtis and colleagues examined how nutritional status and leptin signaling interact with KP-10's ability to stimulate LH secretion in male and female mice. ^[15] Animals were rendered hypophagic by fasting (48 hours) or made leptin-deficient (ob/ob mice), and then received ICV KP-10 (1 nmol). The primary endpoint was plasma LH; secondary endpoints included body weight, food intake, and hypothalamic kisspeptin mRNA expression.

Fasted wild-type mice showed approximately 60% suppression of KP-10-stimulated LH responses compared with fed controls, suggesting that nutritional status modulates sensitivity of the kisspeptin-GnRH pathway downstream of kisspeptin release itself, at the level of GnRH neuron responsiveness or GnRH/LH secretion. Ob/ob mice showed approximately 40% attenuation relative to lean controls. However, peripheral leptin administration (sufficient to normalize body weight in ob/ob mice over two weeks) restored LH responses to KP-10 to near-normal levels, indicating that the metabolic suppression is reversible and leptin-dependent.

These data are important for researchers designing studies in metabolic disease models: KP-10 responsiveness is itself a biomarker of metabolic-reproductive axis status and will vary systematically with nutritional and body-composition variables. Control groups must therefore be carefully matched for feeding status and body weight, not just sex and age.

Study 6: Ramaswamy et al. (2010), Comparative potency of KP fragments in primates

Ramaswamy and colleagues compared the in-vivo LH-stimulatory potency of KP-10, KP-13, and KP-54 in adult male rhesus macaques following intravenous bolus injection. ^[16] On a molar-dose basis, KP-54 consistently produced larger and more prolonged LH responses than KP-10, despite identical receptor pharmacology in-vitro. Pharmacokinetic analysis showed that KP-54 had a plasma half-life approximately 10-fold longer than KP-10 (mean 27 minutes vs. 3 minutes following IV injection), accounting for most of the in-vivo potency difference. When receptor occupancy was estimated from pharmacokinetic modeling, intrinsic efficacy per unit receptor occupancy was statistically indistinguishable between KP-10 and KP-54.

This study definitively established that the apparent in-vivo potency difference between kisspeptin fragments is pharmacokinetic in origin rather than pharmacodynamic. For researchers selecting a kisspeptin fragment, this means that KP-10 is the appropriate choice when a short-acting, rapidly reversible stimulus is desired, while KP-54 is preferable for sustained activation protocols. The study used a relatively small sample (n=4-6 per group), a limitation partly mitigated by the cross-over, repeated-measures design.

Pharmacokinetics

Kisspeptin-10's pharmacokinetics are characterized by rapid plasma clearance, limited CNS penetration via systemic routes, and route-dependent onset kinetics. These properties are primarily driven by protease susceptibility (neprilysin, dipeptidyl peptidase IV, and non-specific endopeptidases), short-chain length limiting half-life relative to KP-54, and the peptide's moderate molecular weight sitting below the size cutoff for robust CNS penetration. ^[6]

Route-dependent pharmacology

The route of administration is perhaps the single most important study-design variable for KP-10 research, and it deserves detailed consideration. Intravenous bolus delivery provides near-instantaneous Cmax with a half-life of under five minutes in rodents, generating a sharp input function to hypothalamic GPR54 receptors that closely mimics the kinetics of natural kisspeptin pulses from KNDy axon terminals. This makes IV bolus the gold standard for studying acute GnRH/LH secretion dynamics. ^[9]

Intracerebroventricular injection bypasses plasma clearance entirely and delivers KP-10 directly to the cerebrospinal fluid, which communicates with the hypothalamic parenchyma. ICV studies therefore achieve GPR54 occupancy at nanomolar concentrations that would require several orders of magnitude higher systemic doses. ICV data should not be used to extrapolate systemic dose requirements; the two routes study fundamentally different pharmacokinetic scenarios. When researchers compare ICV and systemic studies in the literature, apparent 100-fold or greater potency differences are entirely explained by pharmacokinetics.

Subcutaneous injection produces a slower absorption profile with a prolonged but lower peak, typically achieving plasma Cmax within 15-30 minutes in rodents but at concentrations substantially below IV peak levels for equal administered doses. Subcutaneous bioavailability in rodents has been estimated at 20-40% relative to IV. For studies requiring pulsatile stimulation, subcutaneous injection is less reproducible than IV and ICV routes due to variable absorption from the injection depot.

Intranasal delivery has been explored in a small number of studies as a non-invasive CNS delivery route, exploiting the olfactory and trigeminal nerve pathways that bypass the BBB. Preliminary rodent data suggest partial neuroendocrine activity via intranasal KP-10, but the literature on this route remains sparse and reproducibility across laboratories has been inconsistent. Researchers pursuing intranasal approaches should establish their own dose-response curves and confirm central delivery via independent endpoints.

Purity and Verification

What to expect on a certificate of analysis

A credible CoA for research-grade KP-10 should include at minimum: (1) HPLC chromatogram with retention time, peak integration, and purity percentage stated as area under the curve; (2) mass spectrometry (ESI-MS or MALDI-TOF) with observed and expected m/z values for the [M+H]+ and [M+2H]2+ ions; (3) amino acid analysis or sequence verification confirming the YNWNSFGLRF-NH2 sequence and confirming C-terminal amidation; (4) certificate lot number traceable to the specific batch; and (5) moisture/water content (Karl Fischer titration preferred) to allow accurate mass conversion when preparing working solutions.

For KP-10 at MW 1302.44 Da, the expected ESI-MS signals are approximately m/z 652.2 ([M+2H]2+) and m/z 1302.4 ([M+H]+). Discrepancies of more than 0.5 Da in either ion suggest sequence errors, oxidation artifacts (particularly at Trp3), or incomplete C-terminal amidation. Researchers should request the raw mass spectrum, not just a peak list. ^[17]

Independent verification approach

When batch-to-batch consistency is critical (for example, in multi-week in-vivo studies), independent re-verification using the laboratory's own HPLC or LC-MS instrumentation is best practice. A simple reverse-phase HPLC method using a C18 column with an acetonitrile/water gradient (0.1% TFA) at 214 nm will resolve KP-10 from most common truncation products and oxidized variants. Reference standards for KP-10 are commercially available from Bachem and Sigma-Aldrich for comparison.

Endotoxin testing (LAL assay, limulus amebocyte lysate) is warranted for any KP-10 batch intended for in-vivo animal injection, as endotoxin contamination can artifactually suppress or elevate LH responses (LPS is a known suppressor of GnRH secretion at low doses and can confound reproductive neuroendocrine data). The acceptable endotoxin threshold for rodent in-vivo studies is typically below 1 EU/mg peptide by standard regulatory guidance. See our guide to reading a peptide CoA for a detailed walkthrough of acceptable purity thresholds and red flags.

Batch stability and degradation monitoring

KP-10 in solution is susceptible to Trp3 oxidation (yielding a +16 Da mass shift, detectable by MS), Asn2 and Asn4 deamidation (yielding +1 Da shifts), and N-terminal truncation by aminopeptidases present in serum or improperly handled buffer. These degradation products are inactive at GPR54 and will reduce the effective concentration of active peptide without changing the nominal weighed dose. Any study using KP-10 in cell culture media or in-vivo plasma should account for this instability. Working solutions prepared in sterile saline or PBS (pH 7.4) stored on ice are stable for approximately four to eight hours; longer-term storage in solution requires -80°C in aliquots of single-use volume.

Dosage and Reconstitution

Reconstitution guidance

Detailed reconstitution protocols are available in our guide to reconstituting peptides and guide to calculating research doses. The following summarizes KP-10-specific considerations.

The lyophilized peptide should be equilibrated to room temperature inside the sealed vial before opening to minimize condensation on the powder. The preferred reconstitution solvent is sterile, particle-free water (e.g., bacteriostatic water for lab use) or phosphate-buffered saline at pH 7.4. Acidic solvents (0.1% acetic acid) are sometimes used for poorly soluble peptides but are not required for KP-10 at typical research concentrations. Organic co-solvents are not needed.

Worked numerical examples for common research concentrations

Example 1: 1 mg/mL stock solution from a 10 mg vial. Add 10.0 mL of sterile water to the 10 mg vial. This yields a stock concentration of 1.00 mg/mL = 1000 µg/mL. At MW 1302.44 Da, this corresponds to 767.9 µM (approximately 0.77 mM). This stock is suitable for preparation of diluted working solutions and should be aliquoted into 0.2-0.5 mL fractions and stored at -80°C.

Example 2: 0.1 mg/mL working solution for IV bolus rodent study. Take 0.1 mL of the 1 mg/mL stock and add 0.9 mL sterile saline. This yields 1.0 mL at 0.1 mg/mL = 100 µg/mL = 76.8 µM. For a 25-g mouse receiving a 1 nmol IV dose (as used in Gottsch et al. for a lower systemic dose approximation), the required volume at 76.8 µM is: 1 nmol / 76.8 nmol/µL = 0.013 mL = 13 µL. A 13 µL tail-vein injection is feasible in adult mice.

Example 3: Dose-response series for cell-based GPR54 assay. Starting from the 0.77 mM stock, prepare 10-fold serial dilutions in assay buffer (HBSS + 20 mM HEPES, pH 7.4) to achieve final well concentrations of 0.1 nM, 1 nM, 10 nM, 100 nM, and 1000 nM. These concentrations bracket the reported EC50 of approximately 1-4 nM and allow full concentration-response curve construction. Note that the final assay volume dilution must account for any serum present in culture media, as serum proteases will reduce effective KP-10 concentration over time; serum-free or heat-inactivated serum conditions are standard for KP-10 cell assays.

Literature-reported research dose ranges

For reference when designing studies: published rodent IV protocols have used KP-10 at literature-reported animal-equivalent doses ranging from 0.05 nmol/kg to 100 nmol/kg. ICV protocols have used 0.1 to 10 nmol per animal. In the Dhillo et al. human volunteer study (conducted under regulatory approval), IV doses of 0.1 to 1.0 nmol/kg were studied. ^[14] These values are provided for protocol design context and do not represent this site's recommendations for any form of human use.

A useful calculational check: at the 10 mg vial scale, and assuming complete reconstitution, researchers have approximately 7,679 nmol of KP-10 available (10,000 µg / 1302.44 µg/nmol = 7,678 nmol). A standard rodent dosing study using 20 mice at 1 nmol IV each requires 20 nmol total, leaving more than 99.7% of the vial for additional experiments or dilution controls. The 10 mg vial thus represents substantial scale for most laboratory applications.

Side Effects and Safety

Preclinical safety profile

In acute rodent toxicity studies, KP-10 at doses several orders of magnitude above those used for LH stimulation has not been reported to cause mortality or gross organ pathology. The peptide's rapid plasma clearance limits systemic exposure duration, which likely contributes to a relatively favorable acute safety profile. No published reports describe organ toxicity, genotoxicity, or carcinogenicity for KP-10 in standard preclinical screening assays, though comprehensive GLP toxicology studies do not exist for this compound in the public domain. ^[18]

Cardiovascular effects

The most significant preclinical safety signal for KP-10 is cardiovascular. Studies using isolated rat and rabbit heart preparations have shown dose-dependent negative inotropic effects at high KP-10 concentrations, with reductions in ventricular contractility observed at concentrations of 100 nM-10 µM. Coronary vasoconstriction has also been reported in some preparations. ^[13] These effects appear to be mediated in part by NPFF receptor activation (NPFF1R and NPFF2R), which are expressed in cardiac tissue and are known to modulate cardiac function. Whether these effects translate to clinically relevant hemodynamic changes at the doses used in the Dhillo et al. human study (which reported only mild flushing) remains uncertain.

Researchers conducting in-vivo studies at high KP-10 doses (above 10 nmol/kg IV in rodents) should consider including cardiac monitoring endpoints (echocardiography, ECG telemetry) if the study design permits. In standard LH-stimulation protocols at doses below 10 nmol/kg IV, cardiac effects have not been prominently reported.

Receptor desensitization and tachyphylaxis

Continuous infusion of KP-10 (as opposed to pulsatile bolus dosing) produces rapid GPR54 receptor desensitization and tachyphylaxis, manifesting as loss of LH secretory responses within 3-6 hours in rodents and sheep. ^[9] This is a pharmacological rather than toxicological phenomenon, but it constitutes a significant confounder in study design. Researchers planning multi-day KP-10 exposure protocols should implement pulsatile delivery or intersperse washout periods between treatment sessions. Recovery of GPR54 responsiveness typically requires 12-24 hours of peptide-free washout in rodent studies.

Oncology considerations

KISS1 was originally identified as a metastasis suppressor gene, and GPR54 signaling has been shown to suppress tumor cell migration and invasion in multiple cancer cell lines in-vitro. ^[4] This anti-metastatic activity adds a dimension to KP-10's research utility in oncology. However, paradoxical pro-proliferative effects in certain tumor contexts have also been reported, and GPR54 expression is heterogeneous across tumor types. Researchers using KP-10 in cancer cell line experiments should characterize GPR54 expression in their specific model system before drawing conclusions.

Off-target pharmacology summary

Beyond NPFF receptors, KP-10 has not been reported to show significant activity at standard receptor panels (opiate receptors, adrenergic receptors, serotonin receptors) at concentrations below 1 µM, based on published radioligand binding screens. ^[3] This selectivity profile is generally favorable for a research peptide, though researchers using supraphysiological concentrations in-vitro should conduct appropriate selectivity controls.

How It Compares

Understanding where KP-10 sits relative to other HPG-axis research peptides and related compounds helps researchers select the right tool for each experimental question. The table below compares KP-10 against the most commonly used related compounds.

Comparative commentary: KP-10 vs. KP-54

The most common choice researchers face is between KP-10 and KP-54. In-vitro, the two peptides are pharmacologically interchangeable at equimolar concentrations, both achieving full agonism at GPR54 with similar EC50 values. The difference emerges entirely in-vivo: KP-54's approximately 5-10 times longer plasma half-life (species-dependent) translates to substantially greater integrated receptor exposure after a systemic bolus, producing larger and more prolonged LH responses. ^[16]

KP-10 is the preferred reagent when the experimental goal requires: (a) acute, short-duration stimulation with rapid on-off kinetics; (b) study of receptor desensitization-recovery dynamics (KP-10's short half-life allows cleaner washout); (c) pulse-reactivation paradigms mimicking endogenous kisspeptin pulses; or (d) lower cost per experiment where multiple doses per animal are planned. KP-54 is preferred for: (a) studies requiring sustained HPG activation over hours; (b) clinical translation contexts where a longer-acting agent is therapeutically relevant; and (c) protocols in large animals where IV catheterization for multiple injections is impractical.

Comparative commentary: KP-10 vs. GnRH

GnRH acts downstream of the kisspeptin/GPR54 system and directly stimulates pituitary gonadotropes; kisspeptin acts upstream and must engage the full hypothalamo-pituitary relay to produce LH responses. This mechanistic distinction has important experimental implications. When the research question concerns GnRH neuron biology (pulse generation, metabolic-reproductive integration, puberty timing), KP-10 is the appropriate tool. When the question concerns pituitary gonadotrope function, GnRH challenge bypasses hypothalamic variables and provides a cleaner readout. Combined KP-10 + GnRH antagonist protocols (where KP-10 is administered with and without GnRH blockade) are frequently used to confirm the hypothalamic locus of action. ^[12]

Where to Buy

Apollo Peptide Sciences lists this product at kisspeptin-10mg, with the 10 mg vial priced at $40.00. See our full Apollo Peptide Sciences supplier review and our detailed kisspeptin-10mg product page for vendor-specific quality documentation, shipping policies, and current promotions.

When evaluating any research peptide supplier for KP-10, the non-negotiable verification criteria are: (1) HPLC purity ≥ 97% (ideally ≥ 98%) with chromatogram provided; (2) mass spectrometry confirmation of correct MW 1302.44 Da and C-terminal amidation; (3) batch-specific CoA (not a generic template); and (4) documented cold-chain shipping for peptide orders. For guidance on assessing supplier quality in general, see our supplier selection guide.

Researchers ordering internationally should verify import regulations for research peptides in their jurisdiction before placing orders. Storage requirements (cold-chain, -20°C minimum for lyophilized product) mean that overnight or two-day shipping with dry ice or cold packs is strongly preferred over standard ground shipping, particularly in warm weather.

Open Research Questions

The kisspeptin/GPR54 system has been studied intensively since 2001, but several mechanistically important questions remain incompletely resolved.

Pulse-frequency encoding and the LH pulse generator

While it is established that pulsatile KP-10 delivery sustains LH pulsatility and continuous delivery causes desensitization, the precise molecular mechanisms by which GPR54 resets between pulses remain incompletely characterized. Whether receptor recycling (after internalization via beta-arrestin pathways) or de-novo receptor synthesis is required for pulse-to-pulse response maintenance is unresolved. ^[8] This question has direct relevance for the design of kisspeptin-based therapeutic interventions for disorders of gonadotropin pulsatility.

Sex steroid feedback integration

Estrogen's positive feedback on LH surge generation involves kisspeptin neurons in the anteroventral periventricular nucleus (AVPV), but the degree to which KP-10 can substitute for or amplify endogenous AVPV kisspeptin signaling is not fully defined. Progesterone's negative feedback has recently been shown to involve GPR54 downregulation at KNDy neurons, but the receptor-level mechanisms are still being characterized. ^[19] These questions are particularly relevant to research in polycystic ovary syndrome and hypothalamic amenorrhea models.

Bone and metabolic endpoints

GPR54 expression in osteoblasts and the observation that Kiss1r knockout mice show altered bone mineral density have raised the possibility that kisspeptin signaling has direct effects on bone remodeling independent of gonadal steroids. ^[20] Similarly, kisspeptin's apparent role in insulin secretion and energy homeostasis is incompletely characterized. Dose-response and temporal dynamics of KP-10 effects in these peripheral systems are very sparsely characterized, and standard research protocols have not been established.

NPFF receptor cross-pharmacology

The RF-amide motif shared between KP-10 and NPFF family peptides means that any in-vivo KP-10 study is potentially confounded by NPFF receptor engagement, particularly at higher doses. The functional consequences of NPFF1R and NPFF2R activation in-vivo (cardiovascular, pain modulation, food intake) add noise to interpretations of KP-10 effects outside the HPG axis. Selective NPFF receptor antagonists are being developed but are not yet widely available as research tools, leaving this confound incompletely controlled in most published studies. ^[3]

FAQ